Ezetimibe vs Obicetrapib/ezetimibe (Evlarco)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: NPC1L1 · full Atherosclerotic Cardiovascular Disease pipeline
Ezetimibe · Zetia
Marketed by Organon
NCT00092586 · Phase 3 · completed
This was a randomized, double-blind trial with a large sample (n=2,904) comparing ezetimibe plus a statin against a statin plus placebo. The primary endpoint, percent change in LDL cholesterol, was clearly met: ezetimibe produced a significantly larger reduction than placebo (p<.001).
Next expected readout: December 2026 · NCT04701242 (registry estimate)
Reported efficacy
Percent change in LDL-C: Percent change in LDL-C: ezetimibe+statin -25.8% vs placebo+statin -2.7%; treatment difference -23.1 percentage points (P<.001) (met)
Result source: NCT00092586
Obicetrapib/ezetimibe (Evlarco)
Marketed by A. Menarini under a licence from NewAmsterdam Pharma
NCT06005597 · Phase 3 · completed
The study was randomized, quadruple-blind, and placebo- and active-controlled, with 407 participants distributed across four treatment groups. All four prespecified LDL-C comparisons significantly favored the obicetrapib-containing treatment, but LDL-C is a laboratory surrogate rather than a hard clinical endpoint, so the evidence is rated moderate.
Reported efficacy
Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days); Effect of Fixed Dose Combination (FDC) Compared to Ezetimibe Monotherapy on LDL-C (84 Days); Effect of Fixed Dose Combination (FDC) Compared to Obicetrapib Monotherapy on LDL-C (84 Days); Effect of Obicetrapib Monotherapy Compared to Placebo on LDL-C (84 Days): Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days): Fixed Dose Combination -45.58% (Standard Error 3.465) vs Placebo 3.03% (Standard Error 3.564) (met)
Result source: NCT06005597
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ezetimibe | Obicetrapib/ezetimibe (Evlarco) |
|---|---|---|
| LDL-C, % change | -27.7% vs -0.9%−26.7 vs placeboNCT0086716540 other results
| —Not reported |
| Non-HDL-C, % change | -55.6% vs -51%−4.6 vs placeboNCT0063915818 other results
| —Not reported |
| ApoB, % change | -49.1% vs -44.7%−4.4 vs placeboNCT0063915817 other results
| —Not reported |
| Lp(a), % change | —Not posted · NCT03872232 | —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT03872232 | —Not reported |
LDL-C, % change
- Ezetimibe
- -27.7% vs -0.9%−26.7 vs placeboNCT00867165
40 other results
- -54% vs -53.8% NCT01370590
- -63.5% vs -57.4% NCT00525824
- -26.7% vs -12.8% NCT00418834
- -59.7% vs -57.4% NCT00525824
- -58.9% vs -58.7% NCT01370603
- -27.4% vs -11% NCT00276484
- -18.7% vs -39.8% NCT02741245
- -55.6% vs -44% NCT02550288
- -59.2% vs -44% NCT02550288
- -24.8% vs -13.8% NCT01154036
- -54.6% vs -39.8% NCT02741245
- -60.5% vs -39.8% NCT02741245
- -30.8% vs -10.9% NCT00276458
- -27.2% vs 0.5% NCT00867165
- -26.9% vs -3.0% NCT00867165
- -24.8% vs 0.2% NCT00867165
- -53.6% vs -46.4% NCT00525824
- -22.5% vs -17.9% NCT00418834
- -16.4% vs -8.4% NCT01154036
- -19.3% vs -8.4% NCT01154036
- -24% vs -6.1% NCT00783263
- -46.5% vs -46.4% NCT00525824
- -18.6% vs -6.1% NCT00783263
- 2.4% vs -8.4% NCT01154036
- -63.6% vs -3.1% NCT03051100
- -45.6% vs -0.2% NCT04770389
- -52.0% vs -1.4% NCT04770389
- -43.5% vs 1.4% NCT04770389
- -44.4% vs -1.5% NCT04770389
- -51.4% vs -2% NCT04770389
- -44.1% vs -0.8% NCT04770389
- -22.8% vs -1.8% NCT01611883
- -12.7% vs -0.2% NCT04770389
- -14.8% vs -1.4% NCT04770389
- -13.4% vs 1.4% NCT04770389
- -13.7% vs -1.5% NCT04770389
- -14.9% vs -2% NCT04770389
- -13.6% vs -0.8% NCT04770389
- -22.9% vs -1.0% NCT00794677
- -25.8% vs -2.7% NCT00092586
- Obicetrapib/ezetimibe (Evlarco)
- —Not reported
Non-HDL-C, % change
- Ezetimibe
- -55.6% vs -51%−4.6 vs placeboNCT00639158
18 other results
- -25.5% vs 0.3% NCT00867165
- -25.4% vs 1.1% NCT00867165
- -24.9% vs -0.3% NCT00867165
- -22.5% vs 1.6% NCT00867165
- -17.5% vs -6.3% NCT01154036
- -18.1% vs -6.3% NCT01154036
- -58.9% vs -52.4% NCT00525824
- -20% vs -15.8% NCT00418834
- -23.5% vs -11.2% NCT00418834
- -18% vs -11.1% NCT01154036
- -50.1% vs -50.2% NCT01370590
- -54.6% vs -52.4% NCT00525824
- -55.4% vs -55.2% NCT01370603
- -23.3% vs -9% NCT00276484
- -26.7% vs -10.2% NCT00276458
- -0.5% vs -6.3% NCT01154036
- -21.3% vs -2.3% NCT01611883
- -22.7% vs -1.3% NCT00794677
- Obicetrapib/ezetimibe (Evlarco)
- —Not reported
ApoB, % change
- Ezetimibe
- -49.1% vs -44.7%−4.4 vs placeboNCT00639158
17 other results
- -21.7% vs -1.4% NCT00867165
- -12% vs -4.9% NCT01154036
- -14% vs -4.9% NCT01154036
- -12.1% vs -7.6% NCT01154036
- -42.6% vs -43.3% NCT01370590
- -49.5% vs -44.2% NCT00525824
- -14% vs -10.8% NCT00418834
- -16.8% vs -7.7% NCT00418834
- -46.1% vs -44.2% NCT00525824
- -48.7% vs -48.3% NCT01370603
- -17.8% vs -7.7% NCT00276484
- -21.4% vs -7.7% NCT00276458
- -4% vs -4.9% NCT01154036
- -31.6% vs -1.2% NCT04770389
- -34.8% vs -0.9% NCT04770389
- -29.7% vs -0.1% NCT04770389
- -18.0% vs -2.6% NCT00794677
- Obicetrapib/ezetimibe (Evlarco)
- —Not reported
Lp(a), % change
- Ezetimibe
- —Not posted · NCT03872232
- Obicetrapib/ezetimibe (Evlarco)
- —Not reported
3-point MACE (% with event)
- Ezetimibe
- —Not posted · NCT03872232
- Obicetrapib/ezetimibe (Evlarco)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Ezetimibe: 4 of 4 rows · Obicetrapib/ezetimibe (Evlarco): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ezetimibe |
|---|---|
| Dropout rate | 1.3%a NCT01611883 · Phase 4 · registry result, not featured evidence show 43 more results— NCT00701727 · Phase 4 · registry result, not featured evidence 20%10 mg NCT00319449 · Phase 4 · registry result, not featured evidence 4.4%Ezetimibe 10 mg + Rosuvastatin 2.5 NCT02748057 · Phase 3 · registry result, not featured evidence · combination 9.5%Ezetimibe 10 mg + Rosuvastatin 5.0 NCT02748057 · Phase 3 · registry result, not featured evidence · combination 0%10 mg NCT02741245 · Phase 3 · registry result, not featured evidence 5.6%10 mg + 2.5 mg NCT02741245 · Phase 3 · registry result, not featured evidence · combination 2.8%10 mg + 5.0 mg NCT02741245 · Phase 3 · registry result, not featured evidence · combination 4.4%10 mg + 10 mg NCT02550288 · Phase 3 · registry result, not featured evidence · combination 4.3%10 mg + 20 mg NCT02550288 · Phase 3 · registry result, not featured evidence · combination 2.5%10 mg + 10 mg NCT01154036 · Phase 3 · registry result, not featured evidence · combination —10 mg + 20 mg NCT01154036 · Phase 3 · registry result, not featured evidence · combination —10 mg + 20 mg NCT01154036 · Phase 3 · registry result, not featured evidence · combination —10 mg + 10 mg NCT01154036 · Phase 3 · registry result, not featured evidence · combination — NCT01370603 · Phase 3 · registry result, not featured evidence 4.3% NCT00867165 · Phase 3 · registry result, not featured evidence —10 mg/20 mg NCT01370590 · Phase 3 · registry result, not featured evidence —10 mg + 10 mg NCT00783263 · Phase 3 · registry result, not featured evidence · combination 2.5%10 mg + 10 mg NCT00783263 · Phase 3 · registry result, not featured evidence · combination —5 mg + 10 mg NCT00783263 · Phase 3 · registry result, not featured evidence · combination 4%5 mg + 10 mg NCT00783263 · Phase 3 · registry result, not featured evidence · combination 21.9%Ezetimibe + Atorvastatin NCT00654095 · Phase 3 · registry result, not featured evidence · combination —Ezetimibe+Atorvastatin NCT00654095 · Phase 3 · registry result, not featured evidence · combination 4.4% NCT00418834 · Phase 3 · registry result, not featured evidence · combination 9.6% NCT00639158 · Phase 3 · registry result, not featured evidence · combination —20 mg NCT00525824 · Phase 3 · registry result, not featured evidence —10 mg NCT00525824 · Phase 3 · registry result, not featured evidence 13.1%20 mg + 10 mg NCT00525824 · Phase 3 · registry result, not featured evidence · combination —20 mg + 10 mg NCT00525824 · Phase 3 · registry result, not featured evidence · combination 8.9%10 mg + 10 mg NCT00525824 · Phase 3 · registry result, not featured evidence · combination —10 mg + 10 mg NCT00525824 · Phase 3 · registry result, not featured evidence · combination 3.1% NCT00276484 · Phase 3 · registry result, not featured evidence · combination 6.1% NCT00276458 · Phase 3 · registry result, not featured evidence · combination — NCT00101439 · Phase 3 · registry result, not featured evidence 18.5%Combination Therapy NCT04770389 · Phase 2 · registry result, not featured evidence · combination 17.2%Ezetimibe Monotherapy NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy 0%bempedoic acid 180 mg, ezetimibe 10 mg, atorvastatin 20 mg NCT03051100 · Phase 2 · registry result, not featured evidence · combination —800 mg NCT01218204 · Phase 2 · registry result, not featured evidence —300 mg NCT01218204 · Phase 2 · registry result, not featured evidence —100 mg NCT01218204 · Phase 2 · registry result, not featured evidence —80 mg + 800 mg NCT01218204 · Phase 2 · registry result, not featured evidence · combination —10 mg + 100 mg NCT01218204 · Phase 2 · registry result, not featured evidence · combination —10 mg + 300 mg NCT01218204 · Phase 2 · registry result, not featured evidence · combination —10 mg + 800 mg NCT01218204 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 1.3%a NCT01611883 · Phase 4 · registry result, not featured evidence show 43 more results— NCT00701727 · Phase 4 · registry result, not featured evidence —10 mg NCT00319449 · Phase 4 · registry result, not featured evidence 0.9%Ezetimibe 10 mg + Rosuvastatin 2.5 NCT02748057 · Phase 3 · registry result, not featured evidence · combination 0%Ezetimibe 10 mg + Rosuvastatin 5.0 NCT02748057 · Phase 3 · registry result, not featured evidence · combination 0%10 mg NCT02741245 · Phase 3 · registry result, not featured evidence 2.8%10 mg + 2.5 mg NCT02741245 · Phase 3 · registry result, not featured evidence · combination 2.8%10 mg + 5.0 mg NCT02741245 · Phase 3 · registry result, not featured evidence · combination 0%10 mg + 10 mg NCT02550288 · Phase 3 · registry result, not featured evidence · combination 0%10 mg + 20 mg NCT02550288 · Phase 3 · registry result, not featured evidence · combination 0.8%10 mg + 10 mg NCT01154036 · Phase 3 · registry result, not featured evidence · combination —10 mg + 20 mg NCT01154036 · Phase 3 · registry result, not featured evidence · combination —10 mg + 20 mg NCT01154036 · Phase 3 · registry result, not featured evidence · combination —10 mg + 10 mg NCT01154036 · Phase 3 · registry result, not featured evidence · combination — NCT01370603 · Phase 3 · registry result, not featured evidence 3.2% NCT00867165 · Phase 3 · registry result, not featured evidence —10 mg/20 mg NCT01370590 · Phase 3 · registry result, not featured evidence —10 mg + 10 mg NCT00783263 · Phase 3 · registry result, not featured evidence · combination 1.6%10 mg + 10 mg NCT00783263 · Phase 3 · registry result, not featured evidence · combination —5 mg + 10 mg NCT00783263 · Phase 3 · registry result, not featured evidence · combination 3%5 mg + 10 mg NCT00783263 · Phase 3 · registry result, not featured evidence · combination 10.3%Ezetimibe + Atorvastatin NCT00654095 · Phase 3 · registry result, not featured evidence · combination —Ezetimibe+Atorvastatin NCT00654095 · Phase 3 · registry result, not featured evidence · combination 3% NCT00418834 · Phase 3 · registry result, not featured evidence · combination — NCT00639158 · Phase 3 · registry result, not featured evidence · combination —20 mg NCT00525824 · Phase 3 · registry result, not featured evidence —10 mg NCT00525824 · Phase 3 · registry result, not featured evidence 5.1%20 mg + 10 mg NCT00525824 · Phase 3 · registry result, not featured evidence · combination —20 mg + 10 mg NCT00525824 · Phase 3 · registry result, not featured evidence · combination 3.3%10 mg + 10 mg NCT00525824 · Phase 3 · registry result, not featured evidence · combination —10 mg + 10 mg NCT00525824 · Phase 3 · registry result, not featured evidence · combination 1.4% NCT00276484 · Phase 3 · registry result, not featured evidence · combination 0% NCT00276458 · Phase 3 · registry result, not featured evidence · combination — NCT00101439 · Phase 3 · registry result, not featured evidence 7.4%Combination Therapy NCT04770389 · Phase 2 · registry result, not featured evidence · combination 3.4%Ezetimibe Monotherapy NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy —bempedoic acid 180 mg, ezetimibe 10 mg, atorvastatin 20 mg NCT03051100 · Phase 2 · registry result, not featured evidence · combination —800 mg NCT01218204 · Phase 2 · registry result, not featured evidence —300 mg NCT01218204 · Phase 2 · registry result, not featured evidence —100 mg NCT01218204 · Phase 2 · registry result, not featured evidence —80 mg + 800 mg NCT01218204 · Phase 2 · registry result, not featured evidence · combination —10 mg + 100 mg NCT01218204 · Phase 2 · registry result, not featured evidence · combination —10 mg + 300 mg NCT01218204 · Phase 2 · registry result, not featured evidence · combination —10 mg + 800 mg NCT01218204 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 2.7%a NCT01611883 · Phase 4 · registry result, not featured evidence show 43 more results0% NCT00701727 · Phase 4 · registry result, not featured evidence 10%10 mg NCT00319449 · Phase 4 · registry result, not featured evidence 1.8%Ezetimibe 10 mg + Rosuvastatin 2.5 NCT02748057 · Phase 3 · registry result, not featured evidence · combination 4.8%Ezetimibe 10 mg + Rosuvastatin 5.0 NCT02748057 · Phase 3 · registry result, not featured evidence · combination 0%10 mg NCT02741245 · Phase 3 · registry result, not featured evidence 0%10 mg + 2.5 mg NCT02741245 · Phase 3 · registry result, not featured evidence · combination 0%10 mg + 5.0 mg NCT02741245 · Phase 3 · registry result, not featured evidence · combination 0%10 mg + 10 mg NCT02550288 · Phase 3 · registry result, not featured evidence · combination 0%10 mg + 20 mg NCT02550288 · Phase 3 · registry result, not featured evidence · combination 0%10 mg + 10 mg NCT01154036 · Phase 3 · registry result, not featured evidence · combination 1.6%10 mg + 20 mg NCT01154036 · Phase 3 · registry result, not featured evidence · combination 2.2%10 mg + 20 mg NCT01154036 · Phase 3 · registry result, not featured evidence · combination 0%10 mg + 10 mg NCT01154036 · Phase 3 · registry result, not featured evidence · combination 1% NCT01370603 · Phase 3 · registry result, not featured evidence 2.2% NCT00867165 · Phase 3 · registry result, not featured evidence 0.5%10 mg/20 mg NCT01370590 · Phase 3 · registry result, not featured evidence 0%10 mg + 10 mg NCT00783263 · Phase 3 · registry result, not featured evidence · combination —10 mg + 10 mg NCT00783263 · Phase 3 · registry result, not featured evidence · combination 0%5 mg + 10 mg NCT00783263 · Phase 3 · registry result, not featured evidence · combination —5 mg + 10 mg NCT00783263 · Phase 3 · registry result, not featured evidence · combination —Ezetimibe + Atorvastatin NCT00654095 · Phase 3 · registry result, not featured evidence · combination 7.5%Ezetimibe+Atorvastatin NCT00654095 · Phase 3 · registry result, not featured evidence · combination — NCT00418834 · Phase 3 · registry result, not featured evidence · combination 1.1% NCT00639158 · Phase 3 · registry result, not featured evidence · combination —20 mg NCT00525824 · Phase 3 · registry result, not featured evidence —10 mg NCT00525824 · Phase 3 · registry result, not featured evidence —20 mg + 10 mg NCT00525824 · Phase 3 · registry result, not featured evidence · combination —20 mg + 10 mg NCT00525824 · Phase 3 · registry result, not featured evidence · combination —10 mg + 10 mg NCT00525824 · Phase 3 · registry result, not featured evidence · combination —10 mg + 10 mg NCT00525824 · Phase 3 · registry result, not featured evidence · combination — NCT00276484 · Phase 3 · registry result, not featured evidence · combination 0% NCT00276458 · Phase 3 · registry result, not featured evidence · combination 0% NCT00101439 · Phase 3 · registry result, not featured evidence 0%Combination Therapy NCT04770389 · Phase 2 · registry result, not featured evidence · combination 7.1%Ezetimibe Monotherapy NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy 0%bempedoic acid 180 mg, ezetimibe 10 mg, atorvastatin 20 mg NCT03051100 · Phase 2 · registry result, not featured evidence · combination 0%800 mg NCT01218204 · Phase 2 · registry result, not featured evidence 0%300 mg NCT01218204 · Phase 2 · registry result, not featured evidence 0%100 mg NCT01218204 · Phase 2 · registry result, not featured evidence 0%80 mg + 800 mg NCT01218204 · Phase 2 · registry result, not featured evidence · combination 0%10 mg + 100 mg NCT01218204 · Phase 2 · registry result, not featured evidence · combination 0%10 mg + 300 mg NCT01218204 · Phase 2 · registry result, not featured evidence · combination 0%10 mg + 800 mg NCT01218204 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a nasopharyngitis 14.7% (placebo 16.9%) type 2 diabetes mellitus 9.3% (placebo 7.8%) hypoglycaemia 2.7% (placebo 9.1%) NCT01611883 · Phase 4 · registry result, not featured evidence show 29 more resultsconstipation 9.7% (placebo 9.7%) contusion 6.5% (placebo 0%) diarrhoea 6.5% (placebo 6.5%) NCT00701727 · Phase 4 · registry result, not featured evidence 10 mg arthralgia 10% (placebo 0%) headache 10% (placebo 0%) myalgia 10% (placebo 0%) NCT00319449 · Phase 4 · registry result, not featured evidence nasopharyngitis 36% back pain 7.9% gastroenteritis 7% NCT02748057 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 38.1% contusion 9.5% liver function test abnormal 9.5% NCT02748057 · Phase 3 · registry result, not featured evidence · combination 10 mg + 2.5 mg nasopharyngitis 8.5% NCT02741245 · Phase 3 · registry result, not featured evidence · combination 10 mg + 5.0 mg nasopharyngitis 9.7% NCT02741245 · Phase 3 · registry result, not featured evidence · combination 10 mg + 10 mg nasopharyngitis 14.7% alanine aminotransferase increased 1.5% NCT02550288 · Phase 3 · registry result, not featured evidence · combination 10 mg + 20 mg nasopharyngitis 17.4% alanine aminotransferase increased 5.8% NCT02550288 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 10.9% (placebo 11.1%) upper respiratory tract infection 7.6% (placebo 2.2%) influenza 5.4% (placebo 6.7%) NCT00867165 · Phase 3 · registry result, not featured evidence nasopharyngitis 36.3% alanine aminotransferase increased 32.9% c-reactive protein increased 21.2% NCT00654095 · Phase 3 · registry result, not featured evidence · combination constipation 1.3% headache 1.3% upper respiratory tract infection 1.3% NCT00418834 · Phase 3 · registry result, not featured evidence · combination muscle spasms 3.7% (placebo 3.3%) diarrhea 3.3% (placebo 2.2%) myalgia 2.6% (placebo 3.7%) NCT00639158 · Phase 3 · registry result, not featured evidence · combination 20 mg myalgia 4.7% dizziness 2.4% nausea 2.4% NCT00525824 · Phase 3 · registry result, not featured evidence 10 mg arthralgia 2.3% myalgia 2.3% headache 1.9% NCT00525824 · Phase 3 · registry result, not featured evidence 20 mg + 10 mg myalgia 2.6% nasopharyngitis 2.6% influenza 2.1% NCT00525824 · Phase 3 · registry result, not featured evidence · combination 10 mg + 10 mg myalgia 2% bronchitis 1.5% headache 1.5% NCT00525824 · Phase 3 · registry result, not featured evidence · combination bronchitis 1.4% headache 1.4% nasopharyngitis 1.4% NCT00276484 · Phase 3 · registry result, not featured evidence · combination fatigue 2.1% nasopharyngitis 2.1% vertigo 2.1% NCT00276458 · Phase 3 · registry result, not featured evidence · combination diarrhoea 7.4% (placebo 0%) abdominal pain 3.7% (placebo 0%) back pain 3.7% (placebo 0%) NCT04770389 · Phase 2 · registry result, not featured evidence · combination diarrhoea 7.1% (placebo 0%) headache 7.1% (placebo 3.6%) bursitis 3.6% (placebo 0%) NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy bempedoic acid 180 mg, ezetimibe 10 mg, atorvastatin 20 mg diarrhoea 4.7% (placebo 0%) fatigue 4.7% (placebo 0%) headache 4.7% (placebo 5%) NCT03051100 · Phase 2 · registry result, not featured evidence · combination 800 mg headache 15.4% (placebo 18.2%) blood calcium decreased 7.7% (placebo 0%) constipation 7.7% (placebo 0%) NCT01218204 · Phase 2 · registry result, not featured evidence 300 mg nausea 33.3% (placebo 0%) constipation 16.7% (placebo 0%) contusion 16.7% (placebo 0%) NCT01218204 · Phase 2 · registry result, not featured evidence 100 mg headache 18.2% (placebo 18.2%) back pain 9.1% (placebo 0%) cough 9.1% (placebo 0%) NCT01218204 · Phase 2 · registry result, not featured evidence 80 mg + 800 mg dizziness 16.7% (placebo 0%) headache 16.7% (placebo 18.2%) abdominal pain upper 8.3% (placebo 0%) NCT01218204 · Phase 2 · registry result, not featured evidence · combination 10 mg + 100 mg headache 27.3% (placebo 18.2%) rash 18.2% (placebo 0%) blood creatine phosphokinase increased 9.1% (placebo 0%) NCT01218204 · Phase 2 · registry result, not featured evidence · combination 10 mg + 300 mg diarrhoea 9.1% (placebo 9.1%) headache 9.1% (placebo 18.2%) rhinorrhoea 9.1% (placebo 0%) NCT01218204 · Phase 2 · registry result, not featured evidence · combination 10 mg + 800 mg back pain 9.1% (placebo 0%) fatigue 9.1% (placebo 9.1%) headache 9.1% (placebo 18.2%) NCT01218204 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ezetimibe
show 40 more results
show 15 more results
show 15 more results
show 18 more results
show 18 more results
show 17 more results
+ 22 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ezetimibe's landscape · Obicetrapib/ezetimibe (Evlarco)'s landscape